Фарит Ахатович Хабиров
Russian Medical Academy of Continuous Professional Education · 110 works · 2,678 citations · h-index 13
Top works
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
- Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP)
- Triple stimulation technique (TST) in amyotrophic lateral sclerosis
- Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP)
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
- Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients
- Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
- Myofascial pain — modern problems of diagnosis and treatment in practice of a primary care physician
- Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
- Provision of alemtuzumab safety is one of the main components of pharmacovigilance
- The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm
- Discogenic lumbosacral radiculopathy. Recommendations of the Russian Association for the Study of Pain (RSSP)
- Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
- Myofascial pain syndrome: practical development of theoretical foundations
- Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
- Assessment of risk factors for mortality in multiple sclerosis
- Multiple sclerosis in the Republic of Tatarstan: epidemiological and clinical characteristics
- Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial